Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immunome, Inc. (IMNM : NSDQ)

• Company Description    Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States. Number of Employees: 118

• Price / Volume Information    Yesterday's Closing Price: $9.21 Daily Weekly Monthly 20 Day Moving Average: 772,474 shares Shares Outstanding: 87.04 (millions) Market Capitalization: $801.68 (millions) Beta: 1.92 52 Week High: $16.73 52 Week Low: $5.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.34% -8.97% 12 Week 4.30% -5.26% Year To Date -13.28% -18.62%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 18702 N. CREEK PARKWAY SUITE 100 - BOTHELL,WA 98011 USA ph: 425-939-7410 fax: - investors@immunome.com http://www.immunome.com

• General Corporate Information    Officers Clay B. Siegall - President; Chief Executive Officer and Director Max Rosett - Chief Financial Officer Isaac Barchas - Director Jean-Jacques Bienaime - Director James Boylan - Director Peer Information Immunome, Inc. (CORR.) Immunome, Inc. (RSPI) Immunome, Inc. (CGXP) Immunome, Inc. (BGEN) Immunome, Inc. (GTBP) Immunome, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45257U108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 87.04 Most Recent Split Date: (:1) Beta: 1.92 Market Capitalization: $801.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.57 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.21 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.98 Price/Cash Flow: - Price / Sales: 63.68 EPS Growth vs. Year Ago Period: -2.04% vs. Previous Quarter: 3.85% Sales Growth vs. Year Ago Period: 69.84% vs. Previous Quarter: 37.22% ROE 06/30/25 - -76.10 03/31/25 - -71.65 12/31/24 - -62.99 ROA 06/30/25 - -65.14 03/31/25 - -60.36 12/31/24 - -52.94 Current Ratio 06/30/25 - 12.13 03/31/25 - 10.49 12/31/24 - 4.08 Quick Ratio 06/30/25 - 12.13 03/31/25 - 10.49 12/31/24 - 4.08 Operating Margin 06/30/25 - -1,469.65 03/31/25 - -1,567.26 12/31/24 - -1,629.52 Net Margin 06/30/25 - -1,687.08 03/31/25 - -1,875.21 12/31/24 - -3,240.38 Pre-Tax Margin 06/30/25 - -1,687.08 03/31/25 - -1,875.21 12/31/24 - -3,240.38 Book Value 06/30/25 - 3.09 03/31/25 - 3.53 12/31/24 - 2.27 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©